Laura Contreras

Laura Contreras

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CACristian Arriaga
Cristian Arriaga
LCLaura Contreras
Laura Contreras
SASergio Aguilar-Villanueva
Sergio Aguilar-Villanueva
JRJUAN ENRIQUE BARGALLO ROCHA
JUAN ENRIQUE BARGALLO ROCHA
José Antonio García GordilloJosé Antonio García Gordillo
José Antonio García Gordillo
LHLuis A. Herrera
Luis A. Herrera
Given their tumor-specific and stage-specific gene expression, long non-coding RNAs (lncRNAs) have demonstrated to be potential molecular biomarkers for diagnosis, prognosis, and treatment response. Particularly, the lncRNAs DSCAM-AS1 and GATA3-AS1 serve as examples of this because of their high subtype-specific expression profile in luminal B-like breast cancer. This makes them candidates to use as molecular biomarkers in clinical practice. However, lncRNA studies in breast cancer are limited in sample size and are restricted to the determination of their biological function, which represents an obstacle for its inclusion as molecular biomarkers of clinical utility. Nevertheless, due to their expression specificity among diseases, such as cancer, and their stability in body fluids, lncRNAs are promising molecular biomarkers that could improve the reliability, sensitivity, and specificity of molecular techniques used in clinical diagnosis. The development of lncRNA-based diagnostics and lncRNA-based therapeutics will be useful in routine medical practice to improve patient clinical management and quality of life.

Verified
Journal Article
Open access
PDF file
MGMiguel Angel Gonzalez-Woge
Miguel Angel Gonzalez-Woge
LCLaura Contreras
Laura Contreras
José Antonio García GordilloJosé Antonio García Gordillo
José Antonio García Gordillo
SASergio Aguilar-Villanueva
Sergio Aguilar-Villanueva
JRJUAN ENRIQUE BARGALLO ROCHA
JUAN ENRIQUE BARGALLO ROCHA
LHLuis A. Herrera
Luis A. Herrera
LncRNAs are noncoding transcripts with tissue and cancer specificity. Particularly, in breast cancer, lncRNAs exhibit subtype-specific expression; they are particularly upregulated in luminal tumors. However, no gene signature-based laboratory tests have been developed for luminal breast cancer identification or the differential diagnosis of luminal tumors, since no luminal A- or B-specific genes have been identified. Particularly, luminal B patients are of clinical interest, since they have the most variable response to neoadjuvant treatment; thus, it is necessary to develop diagnostic and predictive biomarkers for these patients to optimize treatment decision-making and improve treatment quality. In this study, we analyzed the lncRNA expression profiles of breast cancer cell lines and patient tumor samples from RNA-Seq data to identify an lncRNA signature specific for luminal phenotypes. We identified an lncRNA signature consisting of LINC01016, GATA3-AS1, MAPT-IT1, and DSCAM-AS1 that exhibits luminal subtype-specific expression; among these lncRNAs, GATA3-AS1 is associated with the presence of residual disease (Wilcoxon test, p < 0.05), which is related to neoadjuvant chemotherapy resistance in luminal B breast cancer patients. Furthermore, analysis of GATA3-AS1 expression using RNA in situ hybridization (RNA ISH) demonstrated that this lncRNA is detectable in histological slides. Similar to estrogen receptors and Ki67, both commonly detected biomarkers, GATA3-AS1 proves to be a suitable predictive biomarker for clinical application in breast cancer laboratory tests.

Verified
Journal Article
Open access
PDF file
JDJulieta Dominguez-Ortiz
Julieta Dominguez-Ortiz
RARosa Alvarez
Rosa Alvarez
RMROGELIO MONTIEL-MANRIQUEZ
ROGELIO MONTIEL-MANRIQUEZ
Alberto Cedro-TandaAlberto Cedro-Tanda
Alberto Cedro-Tanda
NANicolás Alcaraz
Nicolás Alcaraz
LHLuis A. Herrera
Luis A. Herrera
Hereditary breast and ovarian cancer (HBOC) syndrome is a genetic condition that increases the risk of breast cancer by 80% and that of ovarian cancer by 40%. The most common pathogenic variants (PVs) causing HBOC occur in the BRCA1 gene, with more than 3850 reported mutations in the gene sequence. The prevalence of specific PVs in BRCA1 has increased across populations due to the effect of founder mutations. Therefore, when a founder mutation is identified, it becomes key to improving cancer risk characterization and effective screening protocols. The only founder mutation described in the Mexican population is the deletion of exons 9 to 12 of BRCA1 (BRCA1Δ9–12), and its description focuses on the gene sequence, but no transcription profiles have been generated for individuals who carry this gene. In this study, we describe the transcription profiles of cancer patients and healthy individuals who were heterozygous for PV BRCA1Δ9–12 by analyzing the differential expression of both alleles compared with the homozygous BRCA1 control group using RT–qPCR, and we describe the isoforms produced by the BRCA1 wild-type and BRCA1Δ9–12 alleles using nanopore long-sequencing. Using the Kruskal–Wallis test, our results showed a similar transcript expression of the wild-type allele between the healthy heterozygous group and the homozygous BRCA1 control group. An association between the recurrence and increased expression of both alleles in HBOC patients was also observed. An analysis of the sequences indicated four wild-type isoforms with diagnostic potential for discerning individuals who carry the PV BRCA1Δ9–12 and identifying which of them has developed cancer.

10 November 2021 in Revista del Centro de Investigación de la Universidad la Salle
Verified
Journal Article
Open access
PDF file
CACristian Arriaga
Cristian Arriaga
LCLaura Contreras
Laura Contreras
RMROGELIO MONTIEL-MANRIQUEZ
ROGELIO MONTIEL-MANRIQUEZ
DSDaniela Venegas Suárez
Daniela Venegas Suárez
LHLuis A. Herrera
Luis A. Herrera
Un holobionte es considerado una entidad biológica asociada en simbiosis con microorganismos que complementan sus vías metabólicas, sus funciones fisiológicas y su variación genética. El término hologenoma se refiere a todo el contenido genético del holobionte, es decir, a la suma del genoma del hospedero, sus organelos junto con los genomas del microbioma que lo componen. En la actualidad se ha establecido que existe una relación entre el desarrollo de enfermedades y el microbioma de los humanos, por lo que en esta revisión se describirá el papel del hologenoma en el cáncer y las técnicas de secuenciación masiva en paralelo aplicadas en la hologenómica. El estudio de la hologenómica junto con las tecnologías en secuenciación y bionformática proporcionará información relevante para el desarrollo de nuevas herramientas diagnósticas y su posterior aplicación en la práctica clínica.